Your session is about to expire
← Back to Search
RM-1995 for Head and Neck Squamous Cell Carcinoma
Study Summary
This trial is testing a new cancer treatment that uses light to kill cancer cells. The treatment will be given alone or with another cancer drug to see if it is safe and effective.
- Head and Neck Squamous Cell Carcinoma
- Squamous Cell Carcinoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there an opportunity for participants to join this trial currently?
"According to clinicaltrials.gov, recruitment for this research project is currently in progress. The trial was originally published on the 24th of March 2022 and underwent its last edit on April 6th."
To what extent has RM-1995 been tested for safety and efficacy?
"Based on our assessment, RM-1995 was deemed to have a safety ranking of 1 due to its Phase 1 status that has limited clinical data backing both efficacy and safety."
What is the geographical distribution of this trial's implementation?
"The ongoing clinical trial is being conducted in multiple locations, including UCSF Helen Diller Family Comprehensive Cancer Center (San Francisco, California), UCSD Head and Neck Oncology (La Jolla, Texas) City of Hope National Medical Centre (Duarte, Kentucky) among 6 other sites."
What is the scale of participation in this experiment?
"This clinical trial necessitates the recruitment of 36 eligible patients. UCSF Helen Diller Family Comprehensive Cancer Centre and UCSD Head and Neck Oncology are two of many centres that can facilitate participation in this experiment."
Share this study with friends
Copy Link
Messenger